Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference54 articles.
1. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6 (3):527–535.
2. Kindler HL, Bueno R, Testa J: New biomarkers, surgical controversies, and rationally targeted therapies for malignant mesothelioma. In American Society of Clinical Oncology 2008 Educational Book. Edited by Govindan R. Alexandria, VA: American Society of Clinical Oncology; 2008:354–361
3. Krug LM. An overview of chemotherapy for mesothelioma. Hematology/Oncology Clinics of North America 2005; 19 (6): 1117–1136
4. Lerner HJ, Schoenfeld DA, Martin A, et al.: Malignant mesothelioma: The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983, 52:1981–1985, 1983. doi 10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
5. Steele JP, O’Doherty CA, Shamash J, et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 12:497–499, 2001
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献